一种针对 GPC1 的载吉西他滨生物相容性纳米平台，用于胰腺癌多模式成像和治疗。
A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy.
机构信息
Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, PR China.
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
出版信息
Nanomedicine (Lond). 2019 Sep;14(17):2339-2353. doi: 10.2217/nnm-2019-0063. Epub 2019 Aug 15.
Biomarker-targeted nanocarrier holds promise for early diagnosis and effective therapy of cancer. This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer and . Blood biochemical and histological analyses show that the toxicity of GPC1-GEM-nanoparticles (NPs) was negligible. Both and studies demonstrate that GPC1-GEM-NPs can be used as NIRF/MR contrast agent for pancreatic cancer detection. Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls. This novel theranostic nanoplatform provides early diagnostic and effective therapeutic potential for pancreatic cancer.
基于生物标志物的靶向纳米载体有望实现癌症的早期诊断和有效治疗。本工作成功设计并评价了载吉西他滨（GEM）的多功能金纳米载体，用于针对胰腺癌的近红外荧光（NIRF）/磁共振成像（MRI）和靶向化疗。血液生化和组织学分析表明 GPC1-GEM-纳米颗粒（NPs）的毒性可以忽略不计。和研究均表明，GPC1-GEM-NPs 可作为胰腺癌检测的 NIRF/MR 对比剂。用 GPC1-GEM-NPs 治疗异种移植瘤小鼠显示出比对照组更高的肿瘤抑制效果。这种新型治疗诊断纳米平台为胰腺癌的早期诊断和有效治疗提供了潜在的可能。
Zotero 插件